Fundraising Fox
🦊/Companies
Sign in

Shape Therapeutics

Founded 2018 · 32 employees on LinkedIn · 3 known investors

Find your way into Shape Therapeutics

ShapeTX develops programmable RNA medicines by combining artificial intelligence with RNA technology to address genetic causes of disease.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

Shape Therapeutics was founded in 2018 by Josef von Rickenbach, PhD.

JVJosef von Rickenbach, PhD
Josef von Rickenbach, PhDinCo-Founder

Investors · 3

New Enterprise Associates (NEA)✓ verifiedMenlo Park · $200K – $40M
Decheng CapitalMenlo Park
Mission BiocapitalSan Francisco · $500K

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 2

by search overlap
Aro Biotherapeutics25 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Stoke Therapeutics24 shared keywordsStoke Therapeutics develops RNA-based antisense oligonucleotides to treat severe genetic diseases by restoring protein expression through its TANGO platform, with a lead program in late-stage clinical development for Dravet syndrome and additional programs targeting other genetic disorders of the central nervous system and eye.

Companies competing with Shape Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Shape Raises $112M for RNA-based Gene Therapies for Rett, Like Illsrettsyndromenews.com · Jul 2021Shape Therapeutics Secures $112 Million in Series B Financing to Advance Breakthrough RNA Technology Platforms to Democratize Gene Therapyglobenewswire.com · Jul 2021Shape Therapeutics Gets $35.5m In Funding For RNA-Gene Editing Technology - Healthcare Weeklyhealthcareweekly.com · Nov 2019Shape Therapeutics, Inc. raises $35.5M Series A financing, led by NEA and announces the formation of a world-class Scientific Advisory Board, to advance a first-in-class RNA editing gene therapy platform focused on curing genetic diseases. - CureDuchennecureduchenne.org · Nov 2019

Frequently asked questions

What does Shape Therapeutics do?
ShapeTX develops programmable RNA medicines by combining artificial intelligence with RNA technology to address genetic causes of disease.
Who founded Shape Therapeutics?
Shape Therapeutics was founded by Josef von Rickenbach, PhD in 2018.
Who are Shape Therapeutics's investors?
Shape Therapeutics's investors include New Enterprise Associates (NEA), Decheng Capital, Mission Biocapital.